AnaptysBio, Inc. (NASDAQ:ANAB) Short Interest Down 8.6% in January

AnaptysBio, Inc. (NASDAQ:ANAB) was the recipient of a significant drop in short interest during the month of January. As of January 31st, there was short interest totalling 6,030,000 shares, a drop of 8.6% from the January 15th total of 6,600,000 shares. Currently, 23.3% of the shares of the company are short sold. Based on an average daily trading volume, of 662,000 shares, the days-to-cover ratio is currently 9.1 days.

AnaptysBio Price Performance

Shares of AnaptysBio stock opened at $19.78 on Wednesday. AnaptysBio has a 1 year low of $12.21 and a 1 year high of $41.31. The company has a market capitalization of $601.91 million and a P/E ratio of -3.25. The business has a 50 day moving average price of $15.71 and a 200 day moving average price of $25.54.

Insider Buying and Selling

In related news, Director Ecor1 Capital, Llc purchased 6,646 shares of the stock in a transaction that occurred on Thursday, January 2nd. The shares were purchased at an average price of $12.95 per share, with a total value of $86,065.70. Following the completion of the acquisition, the director now directly owns 7,880,094 shares in the company, valued at $102,047,217.30. This represents a 0.08 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 33.70% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. FMR LLC raised its position in shares of AnaptysBio by 15.3% during the 3rd quarter. FMR LLC now owns 3,309,175 shares of the biotechnology company’s stock worth $110,857,000 after purchasing an additional 438,557 shares during the last quarter. Frazier Life Sciences Management L.P. raised its position in shares of AnaptysBio by 2.0% during the 3rd quarter. Frazier Life Sciences Management L.P. now owns 2,209,189 shares of the biotechnology company’s stock worth $74,008,000 after purchasing an additional 43,598 shares during the last quarter. Vanguard Group Inc. raised its position in shares of AnaptysBio by 8.4% during the 4th quarter. Vanguard Group Inc. now owns 1,843,740 shares of the biotechnology company’s stock worth $24,411,000 after purchasing an additional 143,584 shares during the last quarter. Fairmount Funds Management LLC acquired a new position in shares of AnaptysBio during the 4th quarter worth approximately $24,050,000. Finally, Boxer Capital Management LLC acquired a new position in AnaptysBio in the 4th quarter valued at $17,212,000.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on ANAB shares. UBS Group raised their price target on AnaptysBio from $23.00 to $33.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. Wolfe Research initiated coverage on AnaptysBio in a report on Tuesday, February 4th. They issued an “outperform” rating and a $25.00 price objective on the stock. JPMorgan Chase & Co. lowered their price objective on AnaptysBio from $66.00 to $36.00 and set an “overweight” rating on the stock in a report on Thursday, December 19th. Truist Financial lowered their price objective on AnaptysBio from $30.00 to $20.00 and set a “hold” rating on the stock in a report on Wednesday, December 18th. Finally, Guggenheim lowered their price objective on AnaptysBio from $90.00 to $36.00 and set a “buy” rating on the stock in a report on Thursday, December 12th. Four analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $37.45.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.